Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247336 | 0.76 | PNMT (0.61) | PNMTADRA2AADRA2BADRA2CCD44 | |
| SCHEMBL282079 | 0.72 | CA12 (0.42) | — | |
| SCHEMBL28308553 | 0.70 | PNMT (0.48) | PNMTADRA2AADRA2BADRA2CCD44 | |
| SCHEMBL14742904 | 0.67 | ATM (0.54) | — | |
| SCHEMBL6307312 | 0.66 | HTR2C (0.64) | PNMTCD44MAOBASIC3DRD2 | |
| SCHEMBL6312545 | 0.65 | ALDH1A1 (0.47) | PNMTADRA2AADRA2BADRA2CCD44 | |
| SCHEMBL3730208 | 0.64 | ATM (0.40) | — | |
| SCHEMBL9227699 | 0.64 | ATM (0.40) | — | |
| SCHEMBL5894181 | 0.64 | ATM (0.40) | — | |
| SCHEMBL6304990 | 0.64 | PNMT (0.53) | PNMTADRA2AADRA2BADRA2CCD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625920-B2 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625919-B2 | 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7622592-B2 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7605152-B2 | 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090082320-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2009-03-26 | — | — | US | disclosed |
| US-7402577-B2 | Androstane 17-beta-carboxamides as androgen receptor modulators | MERCK & CO., INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1879889-A1 | PROCESS FOR MAKING FLUORINATED 4-AZASTEROID DERIVATIVES AND INTERMEDIATE THEREOF | Merck & Co., Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7301026-B2 | Process for making fluorinated 4-azasteroid derivatives | MERCK & CO., INC (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1581217-A4 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070088042-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MEISSNER ROBERT S | 2007-04-19 | — | — | US | disclosed |
| EP-1501512-A2 | 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1485095-A1 | FLUORINATED 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040235808-A1 | Androstanes as androgen receptor modulators | WANG JIABING (US) | 2004-11-25 | — | — | US | disclosed |
| US-20040220159-A1 | Androstane 17-beta-carboxamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2004-11-04 | — | — | US | disclosed |
| EP-1429779-A2 | ANDROSTANES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004041277-A1 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004033445-A1 | 4-AMINO-AZEPAN-3-ONE COMPOUNDS AS CATHEPSIN K INHIBITORS USEFUL IN THE TREATMENT OF OSTEOPOROSIS | MERCK FROSST CANADA & CO. (CA) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003092588-A2 | 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003077919-A1 | FLUORINATED 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003026568-A2 | ANDROSTANES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088042-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | FSHR, AR, NR5A1 | PNMT 4500/4885ADRA2A 595/4885ADRA2B 566/4885 |
| US-20040220159-A1 | Androstane 17-beta-carboxamides as androgen receptor modulators | CYP19A1, SHBG, AR | PNMT 3069/4885ADRA2A 329/4885ADRA2B 425/4885 |
| US-20090082320-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | FSHR, AR, NR5A1 | PNMT 4500/4885ADRA2A 595/4885ADRA2B 566/4885 |
| US-20040235808-A1 | Androstanes as androgen receptor modulators | SHBG, FSHR, AR | PNMT 3990/4885ADRA2A 206/4885ADRA2B 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.